Testing For Brca Germline Mutations In The Clinic And The Mechanism Of Action Of Parp Inhibitors

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

Dana-Farber Cancer Institute

The Role of Targeting DNA Repair with PARP

Grand Rounds in Urology

PARPi for somatic BRCA1/2 and other DNA repair gene mutations in women with metastatic breast cancer

BRCA Testing in Ovarian Cancer

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander

Detecting Somatic BRCA1/2 Mutations in Ovarian Cancer

Role of PARP Inhibitors in Prostate Cancer

Grand Rounds in Urology

PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry Genetics

PARP Inhibitors in Ovarian Cancer Treatment | Webinar | Ambry Genetics

PARP Inhibitors for BRCA-Associated TNBC

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer

Targeted Oncology

Evaluating Clinical Pathways for Ovarian Cancer Treatment and Maintenance Therapy

Updates in PARP Inhibition and Germline Testing in Prostate Cancer

Grand Rounds in Urology

Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer

Targeted Oncology

PARP Inhibitors

Gynecologic Cancer Education: PARP Inhibitor Therapy

Emerging Options for BRCA-Mutated Breast Cancer Treatment

Germline and Somatic DNA Repair Defects in Prostate Cancer

Grand Rounds in Urology

ACTG Dinner Symposium Highlights | BRCA testing – old story, new opportunities | Dr Shaheenah Dawood